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Summary 
F1 hybrid mice are able to acutely reject parental marrow grafts, a phenomenon that is due to 
natural  killer  type  1-positive (NKI+)  cells.  Circumstantial  evidence had  suggested that  the 
antigenic determinants recognized by these cells are self-antigens, leading to the hypothesis that 
the physiological role of NK1 +  cells is  a  downregulatory  or  suppressive function on bone 
marrow stem cell proliferation and lymphocyte function. In analyzing this hypothesis it is shown 
here that in young mice there is a temporal correlation between appearance of NK1 + cells in 
the  spleen and  the ability  to reject  allogeneic marrow  or  to  suppress endogenous stem cell 
proliferation. The reverse situation exists in mice expressing the homozygous Ipr gene. Whereas 
in young mice cells with NK1 + phenotype are demonstrable, these cells disappear with age, 
i.e., at the time autoimmunity develops. Concomitant with the disappearance of NK1 + cells, 
the ability to reject marrow grafts and to control endogenous stem cell proliferation also vanishes. 
The suggestion that the development of autoimmunity is causally related to the disappearance 
of NK1 + cells is  supported by experiments in which NK1 + cells were either eliminated by 
antibody injection or increased by adoptively transferring cell populations enriched for NK1 + 
cells into Ipr mice. It is shown that removal of cells enhances autoimmunity, whereas injection 
of NK1 + cells delays the onset of autoimmunity. In vitro assays are presented that demonstrate 
that suppression of autoantibody-secreting B cells is due to two NK1 § cell populations, one 
that expresses CD3 and causes specific suppression and one that lacks CD3 and causes nonspecific 
suppression. 
"][  thally irradiated mice have the ability to acutely reject 
certain  allogeneic  and  MHC-matched  bone  marrow 
grafts. In normal and thymus-deficient nude mice, the prin- 
cipal cell type responsible for the rejection is a cell that ex- 
presses cell surface markers characteristic for NK cells as well 
as the CD3 TCR complex (1-3), whereas in SCID mice cells 
with a similar phenotype but lacking TCRs perform this func- 
tion (4). The observation that effector cells with NK pheno- 
type cause the rejection of MHC-matched marrow transplants 
raises the possibility that the responsible cells recognize self- 
antigens. In support of this, it had been shown that cells with 
NK phenotype may cause suppression of endogenous marrow 
stem cell proliferation (5).  This led to the hypothesis that 
the physiological role of these cells is to control marrow stem 
cell proliferation. To examine this hypothesis, we sought to 
correlate the presence of cells with NK phenotype with the 
ability of mice to suppress stem cell proliferation. Here we 
report  that  in young mice the appearance of NK1 + cells 
correlates with the ability to downregulate stern cell prolifer- 
ation, whereas in aging mice with the homozygous lpr gene, 
NK1 + cells disappear concomitant with the loss of ability 
to limit stem call proliferation. Previous observations reported 
by Scribner and Steinberg (6) had shown that the ability of 
mice expressing the Ipr or gld mutations to limit the number 
of endogenous CPU-spleen (S)  1 declines with age. This sug- 
gested that the development of autoimmunity and ability to 
limit endogenous stem cell proliferation are causally related. 
We therefore set out to explore whether there is a correla- 
1 Abbreviations  used in  this paper:  CFU-S,  colony-forming unit-spleen; 
dDNA, denatured DNA; Sn DNA, small pieces of native DNA. 
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Volume 177  January 1993  155-164 tion between the disappearance of cells responsible  for acute 
marrow graft rejection and development of autoimmunity. 
Here we show that this correlation exists  and that in vivo 
ablation of NK1 § cells leads to an earlier devdopment of au- 
toimmunity. In contrast, adoptive transfer of  cell populations 
enriched for NK1 + cells into Ipr mice delays the onset of au- 
toimmunity. It is therefore suggested that the physiological 
role of NK1 + cells is to control both hemopoietic stem cell 
proliferation and B cell function. 
Materials and Methods 
Animals and ln Vivo Procedures.  Female  C57BL/6, C3H/OuJ, 
(C57BL/6  x  C3H)F1 mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Breeding pairs of C57BL/6 lpr and 
C3H gld mice purchased from The Jackson Laboratory were bred 
in our institute. C57BL/6 nu mice were purchased from either The 
Jackson Laboratory or Taconic Farms, Inc. (Germantown, NY). 
For assay of bone marrow graft rejection, bone marrow cells 
were collected by flushing femur and tibia. Marrow transplanta- 
tion was done by intravenous injection of bone marrow cells into 
recipient mice that had received total body "y irradiation of 850 
tad. Success of grafting was assayed  on day 8 posttransplantation 
by counting the number of stem cell  colonies  in the recipient spleen 
(CFU-S) after fixation in Bouin's solution (1). Data are shown as 
scatter graph of individual mice (Fig. 3) or as mean of CFU-S per 
spleen of groups of three to five mice. To determine the number 
of endogenous CFU-S, mice received a dose of 500 tad 3, irradia- 
tion 8 d before examination for CFU-S (7, 8). Data shown repre- 
sent mean +  SD of CFU-S per spleen of groups of three to five 
mice (5). To deplete NK1 § cells, 1-wk-old mice were injected in- 
traperitoneally  weekly  with an increasing  dose  of  mouse  mAb PK136 
(anti-NKl.1) ascites according  to a previously  described  protocol (9). 
Cell Separations, Antibody Treatment, and Cell Cultures.  B cells 
were removed from spleen cell suspensions by adherence on anti- 
Ig-coated  plates (10). Tissue  culture-grade polystyrene  phtes (Falcon 
Labware, Oxnard, CA) were coated with 15/~g/ml a~nity-purified 
goat anti-mouse IgG + IgM (Caltag Laboratories, San Francisco, 
CA) in PBS. The plate was incubated overnight at 4~  and then 
washed five times with PBS before use. A single cell suspension 
of spleen cells was suspended in balanced salt solution (BSS) con- 
taining 10% FCS, and 5  x  107 cells were panned on a 150-mm 
dish in 15 ml of media. Cells were allowed to settle for 1 h at room 
temperature. Halfway  through the incubation the nonadherent cells 
were resuspended  by gently agitating the plate for 30 s. After incu- 
bation nonadherent cells  were collected  by gently agitating the plate 
and washing it three times with BSS. 
For antibody treatment, cells (2  x  107/ml) were incubated for 
45 min at 4~  with the respective antibody at optimal concentra- 
tion, followed  by incubation with low toxicity rabbit serum (Low- 
Tox M; Cedarlane Laboratories, Hornby, Ontario, Canada) as a 
source of C for 45 rain at 37~  Optimal concentrations for each 
antibody were determined  by treating nylon wool-nonadherent cells 
with various dilutions of antibody and C, followed by flow cyto- 
metric analysis to assay the success of the treatment. The mAbs 
T24/31.7 (anti-Thy-1 [11]), PK136 (anti-YK1 [12]), 500-A-2 (anti- 
CD3 [13]), GK1.5 (anti-CD4 [14]), and AD4 (15) (anti-CD8 [15]) 
were prepared from bybridomas grown in our laboratory. 
Cell cultures were set up in RPM11640 supplemented  with 10% 
FCS, 5 x  10 -s M B2-mercaptoethanol,  0.2 mM glutamine, 1 mM 
Na-pyruvate, and 0.1 mM nonessential amino acids, rlL-2 was ob- 
tained from Cetus Corp. (Emeryville, CA). To stimulate expres- 
sion of NK1 and CD3 antigens, spleen cells depleted of B cells 
by panning and of CD4,  as well as CD8 cells by antibody plus 
C treatment, were cultured in the presence of Ib2 for the times 
indicated. Spleen cells from autoimmune mice were cultured for 
2 d in the presence of  4/zg/ml LPS to stimulate antibody secretion 
before enzyme-linked immunospot assay (ELISPOT). 
Immunofluorescence  Staining and ELISPO'E  Indirect  double-color 
immunofluorescence  staining was analyzed on a single-laser  FAC- 
Star Plus  |  (Becton Dickinson & Co., Mountain View, CA). Rat 
antibody RA3-3A1/6.1 (anti-B220 [16]) was obtained from Amer- 
ican Type  Culture Collection (Rockville, MD). Biotin-labehd goat 
anti-hamster IgG antibody (Caltag Laboratories),  FITC-conjugated 
affinity-purified  F(ab')2 fragment of rabbit anti-mouse IgG Fc, and 
biotin-conjugated  a~nity-purified F(ab')2 fragment of goat anti-rat 
IgM (Jackson Immunoresearch,  Avondale,  PA) were used as second 
antibodies. PE-conjugated streptavidin was purchased from Tago 
Corp. (Burlingame, CA). Antibodies were used at optimal con- 
centrations for staining (8). Gates in double staining experiments 
were set with second antibody controls. 
DNA-coated plates were prepared by precoating 96-well flat- 
bottomed tissue culture polystyrene plates (Falcon 3070; Becton 
Dickinson & Co.) with 0.02% methylated  BSA in carbonate  buffer. 
Plates were incubated overnight at 4~  and 100/zl of small pieces 
of native DNA (Sn DNA) and denatured DNA (dDNA)  (100 
/~g/ml) in 0.14 M Tris-buffer saline (TBS), pH 7.4, were added 
then incubated overnight at 4~  Both types of DNA were pre- 
pared following described methods (17). For Ig ELISPOTs, plates 
were coated with 100/~1 goat anti-mouse IgG  +  IgM (Caltag 
Laboratories) (10/zg/ml) in PBS then incubated overnight at 4~ 
Plates were washed and blocked by incubation with 3% BSA/PBS 
(100/~l/well) for 3 h at 37~  Plates were washed three times with 
100 #1 BSS and incubated with 0.2-1  x  10  s cells per well in 100 
/~13% FCS DME at 37~  for 4 h. Plates were washed extensively 
to remove all cells before adding anti-mouse IgG +  IgM biotin- 
conjugated antibodies (Southern Biotechnology Associates) at 100 
#l/well in 3% BSA/PBS/0.05% Tween 20. After incubation over- 
night at 4~  plates were washed, and streptavidin alkaline phos- 
phatase (Southern Biotechnology Associates), 1:1000, 100 #l/well 
in 3% BSA/PBS/Tween  20, was added followed  by incubation for 
2 h at 37~  Plates were washed, and 100/~l/well bromochloroin- 
dolyl phosphate (BCIP; Sigma Chemical Co., St. Louis, MO) was 
added in substrate buffer, 0.5% agarose (kept at 55"C to prevent 
solidification). Plates were incubated for 3 h at 37~  (17-19). 
Results 
In Young Mice the Abilities to Reject Marrow Grafts and to 
Downregulate Endogenous CFU.S Develop Concositandy with 
Appearance of NK1 §  Cells.  It  is  well  documented  that 
young mice up to the age of 3 wk lack the ability to acutely 
reject marrow grafts (20). In agreement with this, it is seen 
in Fig. I that BCF1 mice transplanted with BALB/c marrow 
fail to reject grafts up to the age of 23 d. Thereafter resis- 
tance develops gradually so that by day 32 complete ability 
to  reject  marrow  is  demonstrable.  To  examine  whether 
manifestation of resistance  correlates  with  appearance  of 
NK1 + cells, B as well as T  call-depleted spleen cells from 
BCF1 mice were cultured in ID2-containlng medium to stimu- 
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Figure  1.  Comparison of appearance of alloresistance and endogenous 
CFU-S in newborn BCF1 mice. Mice of various ages were irradiated with 
850 rad then transplanted with 2  x  10  s BALB/c bone marrow for deter- 
mination of alloresistance (&). Littermates were irradiated with 560 rad 
to determine endogenous  CFU-S (0). Animals were killed 8 d after ir- 
radiation or bone marrow transplantation.  SD values of groups of three 
to five mice are plotted. 
late antigen expression (1, 3). 5 d later cells were harvested 
and stained for expression of NK1 and CD3. Fig.  2, A  and 
B, shows that cell populations from 10- or 17-d-old mice do 
not possess NK1 + CD3-  or NK1 + CD3 + cells. Cells from 
21-d-old mice (Fig. 2 C) contain a few dimly staining NK1 + 
CD3-  and NK1 + CD3 + cells. These two populations are 
much more dearly defined in cultures from 30- or 36-d-old 
mice (Fig.  2, D  and E).  It therefore appears  that cells ex- 
pressing NK1 or NK1 and CD3 are demonstrable in the spleen 
of young mice at the time alloresistance to marrow grafts 
develops, whereas these cells are not present in younger mice 
not expressing resistance. 
We had previously provided evidence for a physiological 
function of NK1 + cells in the suppression of endogenous 
CFU-S  proliferation  (5).  If NK1 +  cells  indeed have  this 
function, one would predict that the ability of young mice 
to reject allogeneic marrow should correlate with the ability 
to control the proliferation of endogenous CFU-S.  To ex- 
amine this,  mice of various ages were irradiated with 560 
tad then assayed for endogenous CFU-S. Fig. 1 shows that 
10-d-old mice have very high numbers of CFU-S but that 
with  increasing  age  the  number  of CFU-S  decreases  so 
that  at the age of 22 d  values  common to adult mice are 
reached. This shows that in young mice the appearance of 
NK1 + cells correlates not only with the ability to reject al- 
logeneic marrow grafts but also with the ability to suppress 
endogenous marrow stem cell proliferation. 
In C57BL/6 Ipr Mice the Development of Autoimmunity Cone. 
fates with Loss of  Ability to Suppress Endogenous Stem Cell Prolifer- 
ation and Ability to Reject Allogeneic Bone Marrow.  It had been 
reported that C57BL/6 mice with the homozygous Ipr gene 
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Figure 2.  Age-dependent appearance 
of NK1 + CD3- and NK1 + CD3 + cells 
in the spleen of BCF1 mice. Spleen cells 
were depleted of B cells by panning for 
Ig + cells and depleted of T cells by treat- 
ment with anti-CD4 and anti-CD8 plus 
C before culture. Live cells were isolated 
by Ficoll gradient centrifugation then cul- 
tured for 5 d in 20 U/ml Ib2 followed 
by staining for NK1 and CD3. Shown 
are staining patterns of cells from mice 
of different ages: (A) 10 d; (B) 17 d; (C) 
21 d; (D) 30 d;  (E) 36 d. 
lack the ability to suppress  endogenous stem cell prolifera- 
tion (6). Therefore, if indeed NK1 + cells are responsible for 
regulation of stem cell proliferation, one would predict that 
in lpr mice the ability to suppress endogenous CFU-S disap- 
pears concomitantly with ability to reject allogeneic marrow 
grafts.  To  examine this  prediction,  C57BL/6  Ipr mice of 
varying ages were assayed for B cells secreting autoantibody 
to monitor the development of autoimmunity. Litter mates 
were irradiated and assayed for endogenous CFU-S. Table 1 
shows that 7-wk-old normal mice possess only a low number 
of anti-DNA antibody-secreting B cells in their spleens. This 
is in contrast to C57BL/6 lpr mice of this age, which contain 
significantly higher number of cells that secrete anti-DNA 
antibody. Moreover, this number increases dramatically be- 
157  Takeda  and Dennert Table  1.  In Aging  C57BL/6  Ipr Mice the Number of Anti-DNA  Antibody-producing B  Cells Increases Concomitantly with 
an Increase of Endogenous CFU-S 
ELISPOTS per  10  s cells 
Animals  Fresh  Culture* 
Endogenous 
Strain  Age  CFU-S  Sn DNA  dDNA  Sn DNA  dDNA 
C57BL/6  7  wk  2.3  +  0.60  1.3  +  1.2  3.3  +  1.5  8.3  +  1.5 
C57BL/6  7  mo  2.0  +  0.01  1.3  +  1.2  5.3  +  1.5  10.6  +  1.5 
C57BL/6 lpr  7  wk  1.0  +  1.00  6.7  +  3.5  6.3  +  0.6  25.5  +  0.7 
C57BL/6 Ipr  7  mo  23.1  _+  11.2  46.3  +  3.8  44.0  +  5.3  107.0  _+  7.8 
10.0  +  1.0 
18.0  +  2.0 
26.0  _+  2.0 
107.0  +_  3.6 
* Cells were cultured for 2 d in the presence  of LPS. Data given were derived  from three individual  mice. 
tween the age of 7 wk and 7 mo. Assay for endogenous CFU-S 
reveals a similar effect. 7-wk-old lpr mice express  a normal 
number of endogenous CFU-S that is increased 10 times in 
7-too-old mice, a result that is not seen in normal mice. To 
assay the ability of C57BL/6  Ipr mice to reject allogeneic 
marrow grafts, mice of varying ages were irradiated and then 
transplanted with BALB/c bone marrow. Fig. 3 shows that 
normal C57BL/6  mice regardless of age reject a dose of 106 
BALB/c bone marrow.  Quite a different result is  seen in 
C57BL/6 lpr mice. Recipients up to the age of 2 mo reject 
C57BL/6  +/+  C57BL/6  Ipr/Ipr 
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Figure  3.  C57BL/6 Ipr mice lose the ability to reject aUogeneic  marrow 
grafts with age. C57BL/6 or C57BL/6 Ipr mice were irradiated with 850 
tad and  transplanted  with  106 BALB/c bone marrow cells. On day 8 
animals were killed and spleen colonies counted. CFU-S of individual mice 
of different  ages are plotted. Loss of ability to reject marrow is seen in 
old Ipr but not in normal mice. 
the graft, whereas animals aged 4, 7, or 9 mo grow increasing 
numbers of CFU-S, i.e.,  they lose the ability to reject the 
transplant.  These results therefore show that in mice expressing 
the homozygous Ipr gene the development of autoimmunity 
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Figure  4.  NK1 + CD3- and NK1 § CD3 § cells disappear with age in 
C57BL/6 Ipr (C and D) but not in normal mice (.4 and B). Spleen cells 
were depleted  of B cells and T  cells then cultured for 5 d in 20 U/ml 
IL-2 followed by staining with NK1 and CD3. (.4) C57BL/6, 7 wk old; 
(B) C57BL/6, 9 mo old; (C) C57BL/6 Ipr, 7 wk old; (D) C57BL/6 Ipr, 
9 mo old. 
158  NK1 CD3 Cells and Autoimmunity Table  2.  Injection of CD3 13220 Cells Does Not Suppress the Ability to Reject Allogeneic Marrow Grafts in Young C57BL/6  liar Mice 
Bone marrow 
Adoptive cell 
Kecipients  Donor  transfer*  CFU-S 
C57BL/6  Ipr  l0  s C57BL/6  -  24  •  4.5 
C57BL/6 lpr  los C57BL/6  2.5  x  107 B220 CD3  25  •  5.5 
C57BL/6 Ipr  106 BALB/c  -  <1 
C57BL/6 Ipr  106 BALB/c  2.5  x  107 B220 CD3  <1 
* B220 CD3 cells were enriched from 8-mo-old C57BL/6 lpr spleen by B cell panning followed by treatment with anti-CD4 and anti-CD8 + C. 
Cells were injected 1 d before marrow transplanation into 8-wk-old recipients. 
correlates with loss of ability to control endogenous  stem 
cell proliferation as well as ability to reject allogeneic marrow. 
In Aging C57BL/6  Ipr Mice NK1 + Cells Disappear.  The 
observation  that  a correlation exists between development 
of autoimmunity and loss of functions attributed to NK1 + 
cells raises the question whether this loss of function is reflected 
in the disappearance of cells with this phenotype from the 
spleen of mice developing autoimmunity. To find out, B and 
T  cell-depleted spleen cells from Ipr mice were cultured in 
Ib2 for 5 d, as in Fig.  2,  followed by staining with NK1- 
and CD3-specific antibody. Results  show that the staining 
pattern of cells from normal (Fig.  4 A) and Ipr (Fig. 4  C) 
mice aged 7 wk is essentially the same and that a significant 
proportion of cells express either NK1  or NK1 and CD3. 
Quite in contrast, the cell population from 9-mo-old Ipr (Fig. 
4  D)  but  not  normal  mice  (Fig.  4  B)  lacks  both  NK1 + 
CD3-  as  well as  NK1 +  CD3 +  cells.  It  therefore appears 
that in Ipr mice developing autoimmunity, NK1 § CD3-  as 
well as  NK1 +  CD3 +  cells disappear. 
It is well documented that in Ipr mice with autoimmune 
symptoms there is a concomitant development of lymphade- 
nopathy reflected in a dramatic increase of cells expressing 
B220 and CD3  (see below).  It was  therefore possible that 
the disappearance of NK1 + cells from aging Ipr mice is due 
to the emergence of B220 + CD3 + cells. To examine wheth- 
er  B220 +  CD3 +  cells  cause  functional  loss  of  effectors 
responsible for acute marrow graft rejection, cell populations 
from old Ipr mice enriched for B220 + CD3 + cells were in- 
jected into young Ipr mice. Recipient mice were then tested 
for ability to reject allogeneic marrow grafts. Results show 
(Table 2) that mice that had received one spleen equivalent 
of CD3 + B220 + cells and then were transplanted with ei- 
ther syngeneic or allogeneic bone marrow reject the allogeneic 
but not the syngeneic graft. This demonstrates that B220 + 
Table  3.  Cell Populations from Normal and Nude Mice but Not from  Old Ipr Mice Suppress Autoantibody Secretion in lpr B  Cells 
Cell culture*  ELISPOTS per l0  s cells 
NK1 + cells  B cells  Sn DNA (inhibition)  dDNA  (inhibition) 
-  C57BL/6 Ipr  76.2  •  6.4  85.8  _+  4.6 
C57BL/6  (7 wk)  -  2.4  •  2.6  2.6  •  1.8 
C57BL/6  (7 wk)  C57BL/6 lpr  52.8  •  3.9 (31%, p  <0.001)  54.0  _+  3.0 (37%, p  <0.001) 
C57BL/6 Ipr (7 wk)  -  4.2  •  0.4  4.2  +  1.1 
C57BL/6 l  W (7 wk)  C57BL/6 lpr  55.2  __. 8.7 (28%, p  <0.01)  54.7  _+  2.6 (36%, p  <0.001) 
C57BL/6 lpr (9 too)  -  3.5  _+  2.3  2.4  _+  1.8 
C57BL/6 lpr (9 too)  C57BL/6 lpr  71.7  •  5.4 (6%,  NS)  81.4  +  6.4 (5%,  NS) 
C57BL/6 nude (11 wk)  -  2.0  •  1.6  1.6  •  1.1 
C57BL/6 nude (11 wk)  C57BL/6 Ipr  30.1  _+  4.8 (61%, p <0.001)  30.1  •  6.2 (65%, p  <0.001) 
* NK1 § cells were enriched from spleen cells by B cell panning and treatment with anti-CD4 and anti-CD8 + C, then mixed with B cells at a ratio 
of 1:1 followed by culture in medium containing 4 #g/rnl LPS for 2 d.  To isolate B cells, spleen cells were treated with anri-Thy-1  +  C. 
NK1 +-cunt~inlng populations were from spleens of normal, nude, or Ipr mice of different ages and B cells were from 9-wk-old Ipr mice. 
159  ~  and Dennert Table  4.  (CS7BL/6  x  C3H)FI  Cells Suppress B  Cells from C57BL/6 More Efficiently than B  Cells from C3H 
Cell culture*  ELISPOTS per 2  x  104 cells 
NK1 + cells  B cells  Ig (inhibition) 
ELISPOTS per 10  s cells 
Sn DNA (inhibition)  dDNA (inhibition) 
BCF1 
-  C57BL/6 
BCF1  C57BL/6 
BCF1 
-  C3H 
BCF1  C3H 
BCF1 
-  C57BL/6  lpr 
BCF1  C57BL/6  Ipr 
BCF1 
-  C3H gld 
BCF1  C3H gld 
2.0  +  1.0 
34.7  +  3.1 
15.3  +  6.4  (56%, p  <0.01) 
2.0  +_  2.3 
27.0  _+  2.6 
21.5  _+  2.0 (20%, p  <0.05) 
4.6  _+  2.7 
83.0  _+  6.8 
39.2  _+  4.6  (53%, p  <0.001) 
5.8  _+  3.8 
79.2  _+  7.8 
57.3  _  7.7  (28%, p  <0.01) 
5.0  _+  2.3 
88.6  +_  6.4 
43.6  _+  2.7 (51%, p  (0.001) 
8.0  -+  1.9 
89.2  _+  1.3 
66.5  _+  1.6  (26%, p  <0.001) 
" Culture  conditions and enrichment of NK1 + cells were identical to those in Table 3. 
CD3 §  cells have no  effect on the ability to reject marrow 
grafts, consistent with the interpretation that B220 + CD3 + 
cells do not interfere with the function of cells responsible 
for acute marrow  graft rejection. 
NK1 + Cells  Are Able  to  Cause Specific  as  Well  as Non- 
specific Suppression of B  Cell Ig Secretion In  Vitro.  Since in 
lpr mice the disappearance of NK1 + cells correlates with de- 
velopment of autoimmunity, we sought to explore whether 
cells with this phenotype express suppressive effects on B cell 
Ig  secretion.  To  examine  this,  NK1 +  cells were  enriched 
from normal or C57BL/6  Ipr spleen by depletion of B  and 
T cells, then mixed with B cells from C57BL/6 Ipr. Cell mix- 
tures were cultured for 2 d in the presence of LPS to stimu- 
late  Ig  secretion.  Table  3  shows  that  cells  from  normal 
C57BL/6  mice suppress Ig secretion of C57BL/6 Ipr B cells 
31-37%,  and a very similar suppression is seen when cells 
from 7-wk-old lpr mice were tested (28-36%).  In contrast, 
cells from 9-mo-old Ipr mice have very little suppressive effect 
Table  5.  Cells That  Coexpress NK1  and CD3 Are Responsible for Specific Suppression B  Cell Ig Secretion 
Ceil culture* 
NK1 § cells  ELISPOTS per 10  s cells 
Strain  Treatment  B cells  Sn DNA (inhibition)  dDNA (inhibition) 
-  -  C57BL/6  Ipr  86.6  +  3.4  90.4  _+  4.2 
BCF1  -  C57BL/6  Ipr  45.4  _+  8.0 (48%, p  <0.001)  48.8  -+  6.8  (46%, p  <0.001) 
BCF1  c~CD3 + C  C57BL/6  Ipr  70.2  _+  5.0  (19%, p  <0.001)  69.0  -+  5.0 (24%, p  <0,001) 
BCF1  oeNKI+C  C57BL/6  Ipr  79.0  _+  8.3  (9%,  NS)  81.4  _+  7.0 (10%,  NS) 
BCFi  Mix of NK1  and CD3  populations  C57BL/6  Ipr  74.2  _+  3.0 (14%, p  <0.001)  70.0  _+  7.0  (23%, p  <0.00I) 
-  -  C3H gld  78.4  _+  5.5  80.2  +  2.3 
BCF1  -  C3H gld  59.0  _+  7.4  (25%, p  <0.01)  65.0  _+  6.5  (19%, p  ~0.01) 
BCF1  oeCD3 + C  C3H gld  65.0  _+  5.6  (17%, p  <0.01)  61.8  _+  5.5  (23%, p  <0.01) 
BCF1  c~NKI+C  C3H gld  73.6  _+  6.2  (6%,  NS)  74.4  _+  6.7  (7%,  NS) 
BCF1  Mix of NK1  and CD3  populations  C3H gld  63.2  _+  2.9  (19%, p  <0.01)  60.2  _+  9.1  (25%, p  ~0.01) 
* Cell culture and enrichment of cells were identical to those in Table 3. Cell populations containing NK1 + cells  were treated before culture with 
anti-CD3 or anti-NK1 + C as indicated. A mixture of cells treated with either anti-CD3 + C or anti-NK1 + C was also assayed  for its effects  on B cells. 
160  NK1 CD3 Cells and Autoimmunity Table  6.  Injection of Anti-NK1  Causes an Increase in Cells Secreting Autoantibody 
C57BL/6  I  pr mice  Time of 
injected with:  assay  dDNA 
ELISPOTS per l0  s cells 
Fresh  Culture 
Sn DNA  dDNA  Sn DNA 
wk 
-  6  1+1.1 
Anti-NK1  6  2  -+  0.8  (NS) 
-  8  5-+1.6 
Anti-NK1  8  9  -+  1.8  (p <0.01) 
-  12  12  -+  1.7 
Anti-NK1  12  18  -+  1.1  (p <0.001) 
1  +  1.5  15  _+  1.5  16  _+  1.1 
3  +  1.1  (NS)  22  +  1.9  (p <0.001)  21  _+  2.4  (p <0.01) 
6  +  1.2  29  _+  3.6  28  _+  2.7 
9  +  1.5  (p <0.01)  43  +  5.4  (/7 <0.001)  42  +  3.9  (p <0.01) 
12  +  1.5  48  _+  7.8  49  _+  5.5 
17  _  0.8  (p <0.001)  75  _+  5.6  (p <0.001)  67  _+  3.1  (p <0.001) 
* Cells were cultured for 2 d in the presence of LPS. 
(5-6%),  consistent  with  the observation that  old Ipr mice 
lack NK1 + cells. We had previously shown that nude mice 
possess in their spleens a very high number and activity of 
cells responsible for acute marrow graft rejection (3). It was 
therefore interesting  to assay the effects of cell populations 
from these mice. Table 3 shows that cells from C57BL/6 nude 
mice cause by far the  strongest  inhibition  (61-65%). 
Next the effects of spleen cell populations from BCF1 en- 
riched for NK1 + cells were tested. BCF1 mice reject parental 
C57BL/6 but not C3H marrow (1),  therefore,  NK1 + cells 
from these mice should suppress B cells from C57BL/6 but 
not  from  C3H.  To  test  this,  NK1 +  cells  enriched  from 
BCF1 spleen by depletion of B and T  cells were mixed with 
B cells from either C57BL/6 or C3H/OuJ mice. Results (Table 
Table  7.  Injection of Cells from Nude Mice Enriched for NK1 + 
4) show that Ig secretion of C57BL/6 cells is suppressed 56%, 
whereas that of C3H cells is suppressed 20%. A very similar 
result is seen when effector cells are mixed with B cells from 
C57BL/6 lpror C3Hgldmice.  Again there is a 51-53% sup- 
pression of C57BL/6 as opposed to a 26-28%  inhibition of 
C3H B cells. These results show that cell populations from 
BCF1  spleen  express  stronger  suppressive effects on  H-2  b 
compared with  H-2  k B  cells. 
The effector cell populations tested in these assays are het- 
erogeneous, which makes it difficult to know precisely which 
cells are responsible for the observed effects. To analyze this 
question cell populations were treated with antibody and C 
to eliminate cells expressing NK1 and CD3.  Table 5  shows 
that  the  ability  of BCF1  cells  to  inhibit  Ig  secretion  of 
Cells into lpr Mice Delays the Onset of Autoimmunity 
ELISPOTS per los cells 
Fresh  Culture 
C57BL/6  lpr mice*  Time of 
injected  with:  assay  dDNA  Sn DNA  dDNA  Sn DNA 
wk 
-  12  14  _+  1.1  14  +  1.2  47  _  2.6  45  +  4.3 
C57BL/6  nude 
spleen  12  4  +  1.0  (p <0.001)  4  _+ 0.7  (p <0.001)  26  +  1.5  (p <0.001)  15  _+  2.2  (p <0.001) 
-  16  44  +  3.0  38  +  4.1  103  _+  8.3  96  +  7.4 
C57BL/6  nude 
spleen  16  17  _+  3.1  (p <0.001)  16  _+  2.7  (p <0.001)  65  _+  8.7  (p <0.001)  60  _+  6.8  (p <0.001) 
* Cells were cultured for 2 d in the presence of LPS. 
* C57BL/6  lpr mice (also analyzed in Pig. 5, E and F) were injected with cells from C57BL/6 nude spleen. NK1 + cells were enriched from nude 
spleen by removing B cells by panning, resulting in 30-40% NK1 + CD3 + and 20-30%  NK1 + CD3- cells. Cells (5  x  106 per mouse) were inject- 
ed intravenously at the age of 7, 9, and 13 wk. 
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+  C  from 46--48%  to 19-24%, but that there is no effect 
of antibody treatment on suppression of C3H gld B cells 
(19-25%  vs.  17-23%).  This indicates that CD3 § calls are 
responsible for suppression of C57BL/6 Ipr but not of C3H 
gld B cells.  Treatment of BCF1 ceils with anti-NK1  +  C 
abrogates suppressive activity on both C57BL/6 Ipr and C3H 
g/d B cells. A mixture of BCF1 effector cells treated indepen- 
dently with either anti-NK1  +  C or anti-CD3  +  C is not 
able to suppress  C57BL/6 lpr B ceils more efhciently than 
ceils treated with anti-CD3  +  C, which suggests that the 
ceils responsible for suppression of C57BL/6 lpr B ceils coex- 
press NK1 and CD3. When the same mixture of ceils is as- 
sayed on C3H gld B cells, suppression is similar to that seen 
with cells treated with anti-CD3  +  C. These results sug- 
gest that whereas specific suppression of C57BL/6  B calls 
is  due to  NK1 +  CD3 §  cells,  nonspecific suppression by 
NK1 § CD3-  cells acts on C3H B cells and probably also 
on C57BL/6  B cells. 
Removal of NK1 + Cells in Ipr Mice by Antibody Injection Ac- 
celerates the Development of Autoimmunity,  Whereas Injection of 
Cells Enriched for NK1 + Cells Inhibits Autoimmunity.  Our 
e~periments in Ipr mice show that disappearance of NK1 + 
cells correlates with appearance of autoimmunity symptoms. 
This raised the possibility that NK1 + cells play a direct role 
in the control of autoimmunity and that in their absence the 
development of autoimmunity is accelerated. In support of 
this notion, in vitro assays with B cells from normal or lpr 
mice show that both NK1 § CD3 + and NK1 + CD3-  cells 
suppress Ig secretion. Therefore, ffindeed these two cell popu- 
lations were responsible for the in vivo regulation of B cells 
and suppression of autoimmunity, it would be interesting 
to know whether elimination of NK1 + cells from lpr mice 
accelerates the development of autoimmunity. To find out, 
young Ipr mice were injected with anti-NK1 antibody PK136. 
Continued injection of this antibody leads to complete elimi- 
nation of NK1 + cells  (9,  and data not  shown).  Assay of 
splenic B cells from injected or control mice for anti-DNA 
antibody-secreting cells revealed a small but significant in- 
crease at 6 wk. This increase was more pronounced at later 
time points, when antibody-treated mice had 50% more cells 
producing autoantibody (Table 6). Assay of antibody-injected 
or control Ipr mice by fluorometry for cells expressing B220 
and CD3 revealed no significant differences (data not shown). 
These results show that removal ofcens expressing NK1 stimu- 
lates the appearance of autoantibody-secreting B cells in lpr 
mice but has no demonstrable effect on the appearance of 
B220 + CD3 + cells. 
Since removal of NK1 + cells in vivo causes accelerated de- 
velopment of autoimmunity, one might expect that adop- 
tive transfer of cell populations enriched for NK1 + cells into 
lpr mice should delay its development. To examine this predic- 
tion  NK1 + cells  were enriched from C57BL/6  nu  spleen 
cells by depleting spleen cells of B cells (3).  The resulting 
population typically consists of 30-40%  NK1 + CD3 + cells 
and 20-30%  NK1 + CD3-  cells (3).  This cell population 
was adoptively transferred into C57BL/6 lpr mice at the age 
of 7 and 9 wk. At 12 wk animals were killed and tested for 
autoantibody-secreting B cells. Results in Table 7 show that 
uninjected Ipr mice have 14 and 45--47 B ceils per 10  s fresh 
and cultured spleen cells, respectively, whereas animals that 
received adoptive cell transfers have 4 and 15-26 anti-DNA 
antibody-secreting B cells, respectively. This demonstrates that 
whereas 12-wk-old lpr mice have significantly elevated numbers 
of cells producing autoantibody compared with 7-wk-old lpr 
mice (Table 1), animals that received adoptive cell transfers 
have numbers of autoantibody-secreting B ceils comparable 
to those of normal mice or young Ipr mice. By the age of 
16 wk, control Ipr mice have significantly elevated numbers 
of autoantibody-secreting B cells in fresh and cultured spleen 
cells (Table 7), whereas again mice that received adoptive cell 
transfers have much lower numbers of autoantibody-secreting 
ceils (Table 7). However, the number of autoantibody-secreting 
B cells is significantly higher than that of normal mice or 
young lpr mice, which shows that adoptive cell transfers cause 
a significant delay in appearance but not a complete suppres- 
sion of autoimmunity. 
As mentioned above, one of the manifestations of autoim- 
munity in Ipr mice is the development of lymphadenopathy 
caused by accumulation of B220 § CD3 § cells. It was there- 
fore interesting to examine whether Ipr mice that received 
adoptive cell transfers have high or low numbers of these cells. 
Fig. 5, A and B, shows that 6- or 24-wk-old normal C57BL/6 
mice have between 4.1 and 8.9% B220 § CD3 § cells in their 
B cell--depleted spleen cells. Similarly, 6-wk-old Ipr mice possess 
8.6%  B220 § CD3 § cells, but the percentage of these ceils 
increases to 38.5% in 12-wk-old mice (Fig. 5, C and D). 12- 
wk-old mice that received adoptive cell transfers have only 
6.0% B220 § CD3 § cells in their spleen, and this percentage 
increases to 13.1% by 16 wk (Fig. 5, E and F). These results 
show that adoptive cell transfer of cells enriched for NK1 § 
cells suppresses  the appearance of B220 § CD3 § ceils in Ipr 
mice and therefore has a preventive effect on the development 
of autoimmune symptoms. 
Discussion 
The ability of lethally irradiated Ft hybrid mice to acutely 
reject parental marrow grafts has been somewhat of an enigma 
in transplantation immunology. A long-standing explanation 
for this phenomenon has been that hemopoietic histocom- 
patibility (Hh) antigens are responsible for the rejection and 
that expression of these antigens requires homozygosity (21). 
While presently it is not known with certainty whether Hh 
antigens indeed exist, an alternative possibility is that the re- 
jection mechanism responsible involves effector cells that recog- 
nize self-antigens. In support of this, we had previously shown 
that removal of NK1 + cells from normal mice by various 
means may lead to failure to control proliferation of endoge- 
nous CFU-S in lightly irradiated animals (5). In keeping with 
this observation, we show here that in young mice up to 
the age of 3 wk the abilities to reject allogeneic marrow and 
to control endogenous CFU-S proliferation are not demon- 
strable  and  that  both  functions  appear  at  a  time  when 
NK1 + cells are demonstrable. 
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Figure  5.  CD3 + B220 + cells in C57BL/6 and C57BL/6 Ipr mice. All 
spleen cells were depleted of B cells by panning and then stained for CD3 
and B220. (.4) C57BL/6, 6 wk old; (B) C57BL/6, 24 wk old; (C) C57BL/6 
I/r, 6 wk old; (D) C57BL/6 lpr, 12 wk old;  (E) C57BL/6 Ipr, 12 wk 
old. These mice had been injected (5  x  10~ cells per mouse) with cells 
enriched for NK1 + cells  from C57BL/6 nude at the age of 7 and 9 wk. 
(F) C57BL/6 Ipr, 16 wk old, had been injected with the same call popula- 
tions and dose as in E at the age of 7, 9, and 13 wk. 
In normal mice the ability to reject marrow grafts and to 
control endogenous marrow stem cells persists, whereas in 
mice homozygous for the Ipr gene these functions disappear 
concomitant with a loss of NK1 + cells. This pointed to the 
possibility that NK1 + cells play a role not only in control- 
ling  marrow  stem  cell  proliferation  but  also  in  down- 
modulating immune functions.  In attempts to gather  sup- 
port for this, young Ipr mice were treated with antibody to 
remove NK1 + cells. This resulted in a significant increase  in 
autoantibody-secreting B cells. The reverse was accomplished 
by injection  of cell populations  enriched  for NK1 + cells. 
There was suppression  to normal  levels  of the number  of 
autoantibody-secreting B cells consistent with the interpre- 
tation that these cells have downregulatory effects on B cells. 
An interesting observation is that injection of cell popula- 
tions enriched for NK1 + cells into lpr mice causes complete 
suppression of B220 + CD3 + cells responsible for lymphade- 
nopathy at the later stages of the disease. This could indicate 
that  NK1 +  cells  have  immunosurveillance  functions  and 
control the proliferation of B220 + CD3 + cells.  The obser- 
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cation that treatment of Ipr mice with anti-NK1 has no demon- 
strable effect on B220 + CD3 + ceUs has to be interpreted in 
view  of  the  fact  that  NK1 +  cells  develop  from  NK1- 
precursors (3, 22). Therefore, injection of anti-NK1 will not 
remove precursors  of NK1 + cells but may suffice  to cause 
effects on autoantibody-secreting  B cells. 
A very interesting question is precisely which subpopula- 
tion of NK1 + cells is responsible for the observed effects. 
It  is  a well-established  observation  that  NK1 +  cells have 
homeostatic effects on antibody responses (23), but the rela- 
tive contributions  of NK1 + CD3-  and NK1 + CD3 + cells 
have not been elucidated. Our in vitro experiments provide 
clues to answer this question. We show that suppression of 
C3H B  ceils  by BCF1 calls  is due to  NK1 + CD3-  cells, 
whereas  suppression of C57BL/6  B cells is due to NK1 § 
CD3 + effector cells. This is consistent with the interpreta- 
tion  that  NK1 +  CD3-  cells  have  nonspecific,  whereas 
NK1 +  CD3 +  cells  have  specific,  suppressive effects.  One 
could speculate from this that the specific suppressive effects 
demonstrable with NK1 § CD3 + cells are a reflection of the 
in vivo phenomenon  of hybrid resistance.  This is strongly 
supported by the previous demonstration that NK1 + CD3 + 
cells are responsible for acute parental marrow graft rejection 
in BCF1 mice (1). The finding that NK1 + CD3 + cells have 
specific effects is most likely explained by the expression of 
TCKs. Recent experiments have shown that NK1 + CD3 § 
cells possess TCR o~//3 chains and that  a change in one of 
the chains interferes with the function of these cells. Thus, 
in  C57BL/6  mice  expressing  the  TCK  V/35  transgene, 
NK1 +  CD3 +  cells  are present  but  specific  acute marrow 
graft rejection is not demonstrable (24). The absence of TCRs 
on NK1 §  CD3-  cells  is consistent with  their  nonspecific 
suppressive effect although  this does not exclude that  they 
express specificities yet to be uncovered. The observation that 
SCID mice that possess NK1 + CD3- but not NK1 + CD3 + 
cells reject marrow grafts may point to this possibility (4). 
Both NK1 + CD3-  as well as NK1 + CD3 + cells show 
suppressive effects in our in vitro assays. It therefore is likely 
that both cell types act synergistically in vivo. It is difficult 
to design experiments to assess the relative contributions of 
either cell type in the development of autoimmunity.  The 
reason for this is that both cells develop from NK1-  CD3- 
precursors (1, 3, 22) and in normal mice they are not readily 
demonstrable by FACS  |  staining (1, 3) because they express 
low amounts of antigen.  Culture of cells for 2-5 d in Ib2 
causes stimulation of antigen expression, which makes pos- 
sible identification  of both phenotypes by double staining 
(1, 3, 22). Despite this, purification of phenotypically stable 
cell populations from IL-2-cultured ceils turned out to be im- 
possible because of antigen  modulation  (our  unpublished 
results).  Therefore,  isolation  of homogeneous cell popula- 
tions  for in vivo adoptive cell transfer  experiments  is not 
feasible. 
Our finding that NK1 § cells have a downregulatory func- 
tion on the proliferation of bone marrow stem cells is in agree- 
ment with a previous result by Hansson et al.  (25).  These 
authors  reported  that  depletion  of NK1 + cells in  normal 
mice by continued injection of anti-NK1 antibody results in a failure of  injected mice to downregulate myeloid precursors 
in the spleen. These observations as well as those reported 
here point to an important regulatory function of NK1 + 
cells in the immune system and may open the door to the 
treatment of autoimmune disorders. 
This work was supported by U.S. Public Health Service grants CA-37706 and CA-39623. 
Address correspondence to Gunther Dennert, Kenneth Norris Jr. Cancer Center, P.O. Box 33800, 1441 
Eastlake Avenue, Los Angeles, CA 90033-0800. 
Received for publication  10 August  1992 and in revised form  7 October 1992. 
References 
1.  Yankelevich,  B., C. Knobloch, M. Nowicki, and G. Dennert. 
1989. A novel cell type responsible for marrow graft rejection 
in mice: T cells with NK phenotype cause acute rejection of 
marrow grafts. J. Immunol. 142:3423. 
2.  Blazar, B.K., R. Hirsch, R.E. Gress, S.F. Carroll, and D.A. 
Valera. 1991. In vivo administration of anti-CD3 monoclonal 
antibodies on immunotoxins in murine recipients of allogeneic 
T cell depleted marrow for the promotion of engraftment. J. 
Immunol.  147:1492. 
3.  Kikly, K., and G. Dennert. 1992. Evidence for extrathymic 
development of TNx cells: NK1 + CD3 + cells responsible for 
acute marrow graft rejection are present in thymus deficient 
mice. J. Immunol. 149:403. 
4.  Murphy, W.J., V. Kumar, and M. Bennett.  1987. Rejection 
of bone marrow allografts by mice with severe  combined im- 
munodeficiency: evidence that natural killer cells can mediate 
the specifidty of  marrow graft rejection.J. Ex/~ Med. 165:1212. 
5.  Nowicki, M., B. Yankelevich,  K. Kikly, and G. Dennert. 1990. 
Induction of tolerance to parental marrow grafts in F1 hybrid 
mice. Evidence for recognition  of self antigens. J. Immunol. 
144:47. 
6.  Scribner, C.L., and A.D. Steinberg. 1988. The role of splenic 
colony forming units in autoimmune disease. Clin. Immunol. 
Immunopathol. 49:133. 
7.  Till, J.E., and E.A. McCulloch.  1963. Early repair processes 
in marrow cells irradiated and proliferating in viw Radiat. Res. 
18:96. 
8.  Knobloch, C., and G. Dennert. 1988. Loss of F1 hybrid resis- 
tance to bone marrow grafts after injection of parental lym- 
phocytes: demonstration of parental anti F1 T killer cells and 
general immunosuppression in the host. Transplantation  (Balti- 
more). 45:175. 
9.  Koo, G.C.,  F.J. Dumont, M.  Tutt, J.  Hackett,  Jr.,  and V. 
Kumar. 1986. The NK-I.I(-) mouse: a model to study differen- 
tiation of murine NK cells. J. Immunol. 137:3742. 
10.  Mage,  M.G., L.L. McHugh, and T.L. Rothstein. 1977. Mouse 
lymphocytes  with  and  without  surface immunoglobulin: 
preparative scale separation in polystyrene tissue culture dishes 
coated with specifically  purified anti-immunoglobulin. J. Im- 
munol. Methods. 15:47. 
11.  Dennert, G., R. Hyman, J. Lesley,  and I.S. Trowbridge. 1980. 
Effects of  cytotoxic monoclonal antibody specific  to T200 gly- 
coprotein on functional lymphoid cell populations. Cell. Im- 
munol. 53:350. 
12.  Koo, G.C., and J.R. Peppard. 1984. Establishment of mono- 
clonal anti-NKl.1 antibody. Hybridoma. 3:301. 
13.  Havran, W.L., M. Poenie,  J. Kimura, R. Tsien, A. Weiss, and 
J. ALlison. 1987. Expression and function of the CD3-antigen 
receptor  on  mature  CD4+8 +  thymocytes.  Nature (Lond.). 
330:170. 
14.  Dialynas, D.P., D.B. Wilde, P. Marrack, A. Pierres, K.A. Wall, 
W.L. Havran, G. Otten, M.R. Loken, M. Pierres, J. Kappler, 
and EW. Fitch. 1983. Characterization of  the murine antigenic 
determinant designated L3T4a, recognized by monoclonal an- 
tibody GK1.5: expression of  L3T4a by functional T cell clones 
appears to correlate primarily with class II MHC antigen- 
reactivity. Immunol. Rev. 74:30. 
15.  Raulet, D.H., P.D. Gottlieb, and M.J. Bevan. 1980. Fraction- 
ation of lymphocyte populations with monodonal antibodies 
specific for Lyt2.2 and Lyt3.1. J. Immunol. 125:1136. 
16.  Coffman, Ki., and I.L. Weissman. 1981. B220: a B cell-specific 
member  of the  T200  glycoprotein  family. Nature (Lond.). 
289:681. 
17.  Ando, D.G., F.M. Ebling, and B.H. Hahn.  1986. Detection 
of native and denatured DNA antibody forming cells by the 
enzyme-linked immunospot  assay. Arthritis Rheum.  29:1139. 
18.  Ando, D.G., E.E. Sercarz, and B.H. Hahn. 1987. Mechanisms 
of T and B cell collaboration in the in vitro production of anti- 
DNA antibodies in the N2B/N2W F1 murine SLE model. 
f  Immunol. 138:3185. 
19.  Carlsten, H., and A. Tarkowski. 1989. Expression of hetero- 
zygous 1pr gene in MRL mice I. Defective T-cell reactivity 
and polyclonal B-cell activation. J. Immunol. 30:457. 
20.  Cudkowicz,  G., and M. Bennett.  1971. Peculiar immunobi- 
ology of  bone marrow allografts I graft rejection by irradiated 
responder mice. J. EXl~ Med. 134:83. 
21.  Bennett, M. 1987. Biology and genetics of hybrid resistance. 
Adv. Immunol. 41:333. 
22.  Ballas, Z.K., and W. Rasmussen. 1991. Lymphokine activated 
killer cells IV NKI.1 + CD3 + LAK effectors are derived from 
CD4-  CDS-  NKI.1- precursors. Cell. Immunol. 134:296. 
23.  Abruzzo, L.V., and D.A. Rowley. 1983. Homeostasis of the 
antibody  response: Immunoregnlation  by NK cells. Science 
(Wash. DC).  222:581. 
24.  Kikly, K., and G. Dennert. 1992. Evidence for a role of T 
cell receptors in the effector phase of acute bone marrow graft 
rejection: TCR VB5 transgenic mice lack effector cells able 
to cause graft rejection. J. Immunol. In press. 
25.  Hansson, M., M. Petersson, G.C. Koo, H. Wigzell,  and R. 
Kiessling. 1988. In vivo function of natural killer cells as regu- 
lators of myeloid precursor cells in the spleen. Eur.J. Immunol. 
18:485. 
164  NK1 CD3 Cells and Autoimmunity 